Electrical Vagal Nerve Stimulation in Ulcerative Colitis

Ulcerative Colitis Clinical Trial

— EVASION-UC  

Official title:

Electrical Vagal Nerve Stimulation in Ulcerative Colitis - a Double Blind Placebo - Controlled Study of Transcutaneous Vagal Nerve Stimulation in Ulcerative Colitis

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03908073
• Other study ID #: 18/LO/1693
• Status: Terminated
• Phase: N/A
• Start date: October 30, 2018
• Est. completion date: March 15, 2021

Study information

• Verified date: January 2019
• Source: Queen Mary University of London
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

There are approximately 2.5-3 million patients with inflammatory bowel disease (IBD) across Europe, with associated healthcare costs of €4.6-5.6 billion per annum (1). IBD is associated with a significant reduction in quality of life. Treatments directed towards modifying the inflammatory response, such as anti-tumour necrosis factor-alpha (TNF-α) agents, are expensive, can necessitate admission to hospital for their administration and can be associated with side effects (2 3). Thus, the development of a novel non-pharmacological anti-inflammatory intervention, such as electrical vagal nerve stimulation, is warranted.

This is a proof of concept study which aims to investigate whether transcutaneous vagal nerve stimulation is effective at reducing stress induced inflammatory cytokine levels in patients with quiescent ulcerative colitis.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 12
• Est. completion date: March 15, 2021
• Est. primary completion date: March 15, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 76 Years

Eligibility

Inclusion Criteria:

• Males or females between 18 and 76 years of age (inclusive).

• Has a clinical diagnosis of UC at least 3 months before screening according to accepted international guidelines.

• Quiescent disease. Disease activity will be assessed using the validated partial Mayo score and faecal calprotectin of <4 and <250 µg/g (18) respectively, scored within 3 months of entry into the study. Faecal calprotectin <250 µg/g within 2 weeks before study entry to confirm that there has been no change in activity status.

• Stable medications regimen for 3 months prior to entry into the study, defined as no additions to UC treatment or dosage escalations.

• Patient is willing and able to participate in the study for the required duration, can understand and is willing to sign the ICF and agrees to undergo all protocol-related tests and procedures.

• Patient has a BMI between 18 and 35 kg/m2 inclusive.

Exclusion Criteria:

• Has severe extensive colitis and is at imminent risk of colectomy.

• Presence of a stoma or history of a fistula.

• Currently taking any topical or oral corticosteroids.

• Currently taking any anti-TNF therapy, azathioprine, 5-mercaptopurine or methotrexate.

• Is pregnant, lactating or thinking of becoming pregnant during the study period, or of childbearing years and is unwilling to use and accepted form of birth control.

(Female patients of child-bearing potential must have a negative urine pregnancy test at Screening/pre-dose on Day 1 of the study, excluding female patients of non-child bearing potential who are surgically sterile or post-menopausal. [To be considered post-menopausal female patients must be without menses for 12 consecutive months before screening].)

• Patient has unstable acute illness or exacerbation or an unstable chronic illness or chronic disease (other than UC) that may affect assessments for this study as determined by previous physical examination, medical history, vital signs, ECG, and laboratory (serum biochemistry, haematology, urinalysis) assessments. (Note: Non-fasting elevations of cholesterol and triglycerides are not considered clinically significant.)

• Patient with medical history of hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection

• Has known or suspected severe cardiac disease (e.g., symptomatic coronary artery disease, prior myocardial infarction, congestive heart failure (CHF);

• Has known or suspected cerebrovascular disease (e.g. prior stroke or transient ischemic attack, symptomatic carotid artery disease, prior carotid endarterectomy or other vascular neck surgery);

• Has a clinically significant abnormal screening Electrocardiogram (ECG) e.g. second and third degree heart block, prolonged QT interval, atrial fibrillation, atrial flutter, history of ventricular tachycardia or ventricular fibrillation, or clinically significant premature ventricular contraction);

• Has had a cervical vagotomy;

• Has uncontrolled high blood pressure (systolic >160, diastolic >100 after 3 repeated measurements within 24 hours);

• Is currently implanted with an electrical and/or neurostimulator device (e.g.. cardiac pacemaker or defibrillator, vagal neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator, cochlear implant, sphenopalatine ganglion stimulator or occipital nerve stimulator);

• Has been implanted with metal cervical spine hardware or has a metallic implant near the gammaCore® stimulation site;

• Has a history of syncope (within last two years);

• Has a history of seizures (within last five years);

• Has a known history or suspected history of substance abuse or addiction (within last five years);

• Has previously used the gammaCore® device.

Related Conditions & MeSH terms

• Colitis
• Colitis, Ulcerative
• Transcutaneous Vagal Nerve Stimulation
• Ulcer
• Ulcerative Colitis
• Vagal Nerve Stimulation

Intervention

Device:
• Transcutaneous vagal nerve stimulation
The use of a transcutaneous vagal nerve stimulator by the participant

Locations

Country	Name	City	State
United Kingdom	Tamara Mogilevski	London	Select One

Sponsors (1)

Lead Sponsor	Collaborator
Queen Mary University of London

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The effect of active transcutaneous vagal nerve stimulation on LPS stimulated TNF-a production in comparison to sham after the stress protocol	Whole blood taken from the participants is stimulated with LPS. The concentration of TNF-a will be measured using the ELISA technique. TNF-a level of intervention versus sham is the primary outcome measure.	1 year
Secondary	The effect of active transcutaneous vagal nerve stimulation compared to sham on LPS stimulated TNF-a production without the stress protocol	Whole blood taken from the participants is stimulated with LPS. The concentration of TNF-a will be measured using the ELISA technique. TNF-a level of intervention versus sham without the stress protocol is a secondary measure.	1 year
Secondary	Cardiac vagal tone at baseline visits 1 and 2 and post stress protocol	Cadriac vagal tone and autonomic nervous system monitoring is performed in our laboratory using a specialised device called 'powerlab'.; It is able to convert ECG data into autonomic parameters, including vagal tone, which the investigators can then use as an outcome measure.	1 year
Secondary	The effect of active transcutaneous vagal nerve stimulation compared to sham on LPS stimulated Il6 and Il10 production with and without the stress protocol	Whole blood taken from the participants is stimulated with LPS. The concentration of IL6 and IL10 will be measured using the ELISA technique. IL6 and IL10 level of intervention versus sham without the stress protocol is a secondary measure.	1 year